Heparin use is not without consequence as its usage can result in an auto-immune clotting disorder, called heparin-induced thrombocytopenia (HIT). Interestingly, HIT can persist even after heparin has cleared from the body – a mystery that the CBR researchers aimed to solve.
Today, bees are facing many challenges, such as parasites and pesticides, and modern ‘omics technology has emerged as an excellent tool to help disentangle how complex interacting factors are affecting bee health.
Narges Hadjesfandiari discovered a simple way to significantly improve platelet transfusion safety, which will impact patients who suffer from low platelet levels that happen in severe trauma, serious infections, and cancer.
Patients with Inflammatory Bowel Disease (IBD) require surgery at least once in their life time. However, Bernard Lo, a PhD candidate in the research group led by CBR Principal Investigator Kelly McNagny, finds a therapeutic method to block fibrotic processes in IBD.
Researcher Bob Hancock made an important discovery in the fight against superbugs, while his team was looking for a solution to abscesses, a condition where patients develop reoccurring fluid-filled pockets that don’t respond well to traditional antibiotic treatments.
Li Li, a postdoctoral fellow from Mark Scott’s lab at the CBR, along with her colleagues developed a technique to reduce the risk of acute immune response in blood transfusions from D+ donors to D- recipients.
After two decades of major clinical trials aimed at improving the safety of clot-dissolving drugs, the Pryzdial lab marks a new strategy to dissolve clots based on a novel biochemical pathway they discovered.
Jasmine Hamilton from Kizhakkedathu group developed a scaffold for delivering an iron chelator treatment, reducing the number of injections beta-thalassemia major patients could require from 10 per day to 1 per week.